Success Metrics

Clinical Success Rate
83.3%

Based on 10 completed trials

Completion Rate
83%(10/12)
Active Trials
2(13%)
Results Posted
0%(0 trials)
Terminated
2(13%)

Phase Distribution

Ph not_applicable
1
6%
Ph phase_4
3
19%
Ph phase_2
6
38%
Ph phase_3
6
38%

Phase Distribution

0

Early Stage

6

Mid Stage

9

Late Stage

Phase Distribution16 total trials
Phase 2Efficacy & side effects
6(37.5%)
Phase 3Large-scale testing
6(37.5%)
Phase 4Post-market surveillance
3(18.8%)
N/ANon-phased studies
1(6.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

10 of 12 finished

Non-Completion Rate

16.7%

2 ended early

Currently Active

2

trials recruiting

Total Trials

16

all time

Status Distribution
Active(2)
Completed(10)
Terminated(2)
Other(2)

Detailed Status

Completed10
Terminated2
unknown2
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
2
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 26 (37.5%)
Phase 36 (37.5%)
Phase 43 (18.8%)
N/A1 (6.3%)

Trials by Status

terminated213%
unknown213%
completed1063%
active_not_recruiting16%
recruiting16%

Recent Activity

2 active trials
Showing 5 of 16
recruitingphase_3

Arnica Tincture Fot the Treatment of Cutaneous Leishmaniasis II.

NCT06822478
completedphase_3

Combination, Miltefosine Monotherapy for Cutaneous Leishmaniasis in New World

NCT04515186
active_not_recruitingphase_2

The Association of Miltefosine and Pentoxifylline to Treat Mucosal and Cutaneous Leishmaniasis: A Clinical Trial in Brazil

NCT02530697
completedphase_3

Efficacy of Intra-lesional Injections of Glucantime Once a Week or Twice a Week in the Treatment of Anthroponotic Cutaneous Leishmaniasis (ACL)

NCT04340128
unknownphase_2

Low Antimonial Dosage in American Mucosal Leishmaniasis

NCT01301937
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT06822478Phase 3

Arnica Tincture Fot the Treatment of Cutaneous Leishmaniasis II.

Recruiting
NCT04515186Phase 3

Combination, Miltefosine Monotherapy for Cutaneous Leishmaniasis in New World

Completed
NCT02530697Phase 2

The Association of Miltefosine and Pentoxifylline to Treat Mucosal and Cutaneous Leishmaniasis: A Clinical Trial in Brazil

Active Not Recruiting
NCT04340128Phase 3

Efficacy of Intra-lesional Injections of Glucantime Once a Week or Twice a Week in the Treatment of Anthroponotic Cutaneous Leishmaniasis (ACL)

Completed
NCT01301937Phase 2

Low Antimonial Dosage in American Mucosal Leishmaniasis

Unknown
NCT01301924Phase 2

Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis

Completed
NCT03294161Phase 2

Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis

Completed
NCT01032187Phase 4

Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children

Completed
NCT01953744Phase 3

High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus

Terminated
NCT00317629Phase 3

Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis

Terminated
NCT00818818Phase 4

Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients

Completed
NCT00480883Not Applicable

Treatment of Cutaneous Leishmaniasis With Meglumine Antimoniate Versus Meglumine Antimoniate and Allopurinol

Completed
NCT00600548Phase 2

Trial of Miltefosine in Cutaneous Leishmaniasis (Brazil)

Completed
NCT00487253Phase 3

Oral Miltefosine for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia

Unknown
NCT00973128Phase 2

Reduced Doses of Antimony Plus Ranulocyte Monocyte Colony Stimulating Factor (GM-CSF) for Cutaneous Leishmaniasis

Completed
NCT00317980Phase 4

Safety and Efficacy of Low-Dose Pentavalent Antimony for Treatment of Cutaneous Leishmaniasis

Completed

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16